cautiou adcetri print given disappointingli flat sale prior
quarter howev nccn guidelin chang commerci salesforc build could add
upsid surpris model us adcetri sale q/q st impli
q/q growth visibl alpha factset bloomberg estim view
conserv base limit q/q growth respect despit latter
aid price hike miss larg forgiven strong sale guidanc
maintain well impact season headwind see increas downsid
miss given potenti threaten guidanc howev continu like pipelin
diversif remain cautious optimist adcetri could see inflect given
recent april nccn hl guidelin chang improv adcetri recommend hl well
ad combin option incl checkpoint combo rrhl ii increas commerci presenc
physician awar around recent ad indic link hc conf note iii season
strong histor adcetri q/q growth recoveri histor weak perform
model top bottom-lin beat though see potenti continu frustrat core/
growth product model achiev top-lin revenu vs st
non-gaap opex vs st non-gaap net incom vs st
non-gaap ep vs st despit potenti beat across top bottom-lin
caution script trend and/or price-for-volum concess key base-busi product sensipar
neulasta key growth product aimovig suggest potenti miss vs st may temper
excit around could otherwis strong commerci oper quarter link
increas pt expect commerci
see page estimate revis model achiev in-lin top-lin total revenu
vs st factset model larg driven dupix increas
us/glob estim vs st sourc factset
visiblealpha highli impress q/q us script growth lead increas out-year revenu
estim new pt dupix rapid growth asthma support kol
feedback receiv day event spring dupix constant highlight link
sf day takeaway chicago day takeaway howev dupix seen surg
ad asthma continu long-term concern out-year competit next-
gener class robust efficaci oral administr may seat agent
treatment choic atop dermat safeti continu remain clean link jak top-
line data note model slight eylea beat expect sale vs st
factset base net impact higher rebat incent negat headwind recent
payor cost contain initi requir avastin step-though see sf day note link june
ophtho kol call note despit model top-lin beat model bottom-lin gaap/non-gaap
ep vs st diverg could suggest st reflect up-front
remain concern aspect invest thesi one think continu get
earn preview continu follow page
includ estim revis see page model chang
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
focu ultomiri us switch eu commerci potenti ultomiri
drive upsid surpris model net product revenu slightli
st below-st estim larg driven potenti overli
conserv ultomiri expect howev analysi ultomiri switch trend impli
convers us pnh market ultomiri link rnd day note link
hc conf note impli ultomiri sale well estim
st ultomiri recent approv eu link note expect
contribut revenu though expect focu shift eu switch rate
anticip ultomiri discount price strategi conveni advantag impress
efficaci enabl similarli rapid switch
tibsovo may label expans may help sale though anticip commerci
growth take time strengthen continu see real commerci inflect
depend fit unfit aml opportun conserv model tibsovo
revenu vs st visibl alpha weak saw q/q sale
declin due higher expect donut hole season impact management
optimist recent label expans could creat commerci tailwind link ndr note
continu see aml combin key unlock valu much lucr
indic call look detail surround venu initi data
mtap-delet cancer updat mitapivat pkd enrol pipelin
see potenti top-lin beat driven season palynziq
focu larg beyond valrox vosorotid pipelin updat balanc kuvan
generic risk model achiev top-lin beat vs st
driven primarili palynziq revenu vs st remain posit around
palynziq us launch strong linear patient growth commerci reimburs
patient updat fact clinic enrol uniqu pku patient
rem program note durabl gene therapi point major
debat among investor recent top-lin result suggest factor viii fviii level
declin iu/dl year iu/dl year valrox remain well ahead
competitor gene therapi pfe/sgmo detail data patient
isth roche/onc guidanc updat high dose cohort
patient studi expect investor focu shift clinic data vosoritid
achondroplasia guidanc studi shown promis
increas annual growth veloc agv addit height gain month
remain cautiou despit script track suggest potenti
beat vs st conserv model auryxia sale q/q slightli st
given potenti continu headwind auryxia reimburs link takeaway
note recal auryxia sale declin q/q q/q script declin
auryxia script return growth q/q impli
potenti beat sale captur rates/gross-to-net normal
await demonstr management success navig reimbursement/re-
author hurdl initi face call look color around enrollment/
timelin protect innov trial vadadustat competitor mix
read-out link roxa note
decreas rubraca assumpt st model
growth larg depend prostat cancer expans though eu could add surpris
posit see page estimate revis decreas rubraca revenu
vs st factset us script analysi suggest rel flat us sale
quarter actual slight volum declin q/q occur channel track
howev anticip rubraca benefit improv gross-to-net effect
follow season headwind assum vs report
model net impact effect lead net net q/q us rubraca sale
vs report model limit eu sale
howev note eu rubraca sale could add potenti posit surpris given rubraca
launch eu late less one sell month eu sell day tripl vs
script analysi suggest see in-lin quarter script volum growth
throughout larg in-lin st q/q growth assumpt product script
analysi suggest model total us revenu q/q link
hc conf note may conserv given volum growth potenti
headwind inventori drawdown rebat enabl slight beat vs st
q/q factset also note number one-tim mileston payment flow
quarter collabor revenu includ mileston takeda success file
nda japan announc mileston daiichi sankyo launch
minnebro announc may enabl top-lin beat given appear
fulli reflect st
model nerlynx achiev slight recoveri vs shockingli poor revenu
gener howev anticip upsid limit given continu concern around longer-
term trend model nerlynx sale slightli st consensu
factset note nerlynx becom increasingli challeng model surpris
miss repres major diverg script trend previous appear
increasingli congruent recal nerlynx saw q/q declin net sale declin
bottl sold despit script trend suggest volum growth link post-cal
major nerlynx miss post-cal unexpectedli strong continu remain
cautiou nerlynx growth given potenti patient discontinu outstrip new start
patient begin discontinu therapi follow recommend treatment durat
link mathemat model suggest nerlynx sale plateau/declin management
commentari suggest gap sale rep coverag may contribut poor quarter
fill vacanc may help continu remain cautiou around growth
given cautiou physician commentari use nerlynx adjuv metastat
breast cancer set link mackay sf day takeaway
valuat base case sum-of-the-part valuat base pos-adjust npv eylea
dupix blend po kevzara praluent libtayo assumpt support
price target sector perform rate
compani report capit market estim
chang model revenu cog expens expens sg expens oper incom pre-tax incom tax expens net incom dilut exhibit model chang
compani report capit market estim
chang model revenu expens profit expens expens incom incom expens incom gaap mackay earn preview
